Your browser is no longer supported. Please, upgrade your browser.
INCY Incyte Corporation daily Stock Chart
Incyte Corporation
IndexS&P 500 P/E- EPS (ttm)-0.52 Insider Own0.30% Shs Outstand214.75M Perf Week-3.98%
Market Cap14.09B Forward P/E30.99 EPS next Y2.12 Insider Trans-7.28% Shs Float211.77M Perf Month-4.47%
Income-109.20M PEG- EPS next Q0.48 Inst Own94.00% Short Float2.63% Perf Quarter-1.83%
Sales1.80B P/S7.84 EPS this Y-385.10% Inst Trans-1.70% Short Ratio3.66 Perf Half Y-7.06%
Book/sh8.48 P/B7.74 EPS next Y92.63% ROA-4.60% Target Price83.67 Perf Year-32.08%
Cash/sh6.40 P/C10.24 EPS next 5Y31.09% ROE-6.40% 52W Range58.33 - 102.63 Perf YTD-30.74%
Dividend- P/FCF157.23 EPS past 5Y-35.00% ROI-14.80% 52W High-36.08% Beta1.00
Dividend %- Quick Ratio4.00 Sales past 5Y38.90% Gross Margin95.90% 52W Low12.46% ATR2.75
Employees1208 Current Ratio4.00 Sales Q/Q17.90% Oper. Margin-4.70% RSI (14)51.42 Volatility3.86% 4.06%
OptionableYes Debt/Eq0.01 EPS Q/Q-20.30% Profit Margin-6.10% Rel Volume0.58 Prev Close65.42
ShortableYes LT Debt/Eq0.01 EarningsOct 30 BMO Payout- Avg Volume1.52M Price65.60
Recom2.20 SMA200.68% SMA500.24% SMA200-6.44% Volume901,841 Change0.28%
Oct-22-18Upgrade Raymond James Outperform → Strong Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $73
Sep-25-18Initiated Leerink Partners Mkt Perform
Aug-15-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Aug-01-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-26-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Jun-11-18Upgrade Evercore ISI In-line → Outperform
Apr-09-18Reiterated Credit Suisse Outperform $145 → $78
Apr-09-18Downgrade Gabelli & Co Buy → Hold
Apr-06-18Downgrade William Blair Outperform → Mkt Perform
Apr-06-18Downgrade Guggenheim Buy → Neutral
Apr-05-18Reiterated Barclays Overweight $165 → $135
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-21-17Reiterated RBC Capital Mkts Sector Perform $136 → $120
Oct-06-17Resumed Goldman Buy $160
Sep-15-17Initiated RBC Capital Mkts Sector Perform $136
Sep-11-17Upgrade Raymond James Mkt Perform → Outperform
Aug-17-17Initiated Evercore ISI In-line $135
May-12-17Initiated Oppenheimer Perform
Dec-10-18 03:45PM  Why MacroGenics Stock Is Getting Hammered Today Motley Fool
07:58AM  5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks
Dec-06-18 09:20AM  Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger Zacks
Dec-04-18 05:25PM  Incyte (INCY) Announces Positive Data on Jakafi for GVHD Zacks
07:00AM  Today's Research Reports on Trending Tickers: Incyte and Supernus Pharmaceuticals ACCESSWIRE
Dec-03-18 10:00AM  Results of REACH1 Study of Ruxolitinib (Jakafi®) for the Treatment of Acute Graft-Versus-Host Disease Demonstrate Rapid and Durable Patient Benefit Business Wire +6.33%
Dec-02-18 05:51PM  The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs Benzinga
Nov-29-18 09:31AM  Why Is Incyte (INCY) Up 1.5% Since Last Earnings Report? Zacks
Nov-27-18 07:30AM  Incyte Appoints Dr. Dashyant Dhanak as Chief Scientific Officer Business Wire
Nov-23-18 09:10AM  A Look At The Intrinsic Value Of Incyte Corporation (NASDAQ:INCY) Simply Wall St.
Nov-21-18 04:19PM  This Highly Rated Pharma Giant Is More Than Just A Diabetes Player Investor's Business Daily
Nov-19-18 09:49AM  AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down Zacks
Nov-15-18 10:01AM  Merck's Keytruda Improves Survival in Esophageal Cancer Study Zacks
Nov-07-18 08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
Nov-05-18 07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Molson Coors Brewing, Coca-Cola European Partners, Brinker International, Incyte, RPC, and Group 1 Automotive New Research Emphasizes Economic Growth GlobeNewswire
Nov-02-18 11:15AM  Incyte's Shares Have Taken a Beating in 2018 -- Here's Why Motley Fool
Nov-01-18 08:21PM  Scary Markets, Frightening Stocks, and How to Keep From Panicking Motley Fool +5.57%
11:06AM  Edited Transcript of INCY earnings conference call or presentation 30-Oct-18 12:00pm GMT Thomson Reuters StreetEvents
10:36AM  Multiple Abstracts Highlighting Data from Incytes Targeted Therapy Portfolio Accepted for Presentation at the 60th Annual ASH Meeting Business Wire
08:23AM  3 Big Stock Charts for Thursday: Walmart, Prologis and Incyte InvestorPlace
08:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Incyte ACCESSWIRE
Oct-30-18 03:09PM  Incyte Corp (INCY) Q3 2018 Earnings Conference Call Transcript Motley Fool
02:45PM  Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View Zacks
08:30AM  Incyte (INCY) Misses Q3 Earnings and Revenue Estimates Zacks
07:26AM  Incyte: 3Q Earnings Snapshot Associated Press
07:00AM  Incyte Reports 2018 Third Quarter and Nine Month Financial Results and Provides Updates on Key Clinical Programs Business Wire
Oct-28-18 09:33AM  Better Buy: Vertex Pharmaceuticals Incorporated vs. Incyte Corporation Motley Fool
Oct-25-18 02:14PM  Incyte Named a 2018 Top Employer by Science Magazine Business Wire +5.53%
07:30AM  FDA Grants Priority Review for Ruxolitinib (Jakafi®) as a Treatment for Patients with Acute Graft-Versus-Host Disease Business Wire
Oct-24-18 04:49PM  Incyte (INCY) to Report Q3 Earnings: What's in the Cards? Zacks -6.33%
11:19AM  Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod Zacks
Oct-21-18 06:30PM  ACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis PR Newswire
06:45AM  Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma Business Wire
Oct-19-18 10:10AM  Phase 2 GEOMETRY mono-1 Trial of Investigational Medicine Capmatinib Shows Positive Results in Patients with MET-mutated Advanced NSCLC Business Wire
Oct-17-18 09:15AM  Stocks Jump 2%+ on Solid Earnings Zacks
Oct-12-18 08:15AM  Report: Developing Opportunities within Packaging Corporation of America, Jones Energy, Pitney Bowes, Mercury General, Invacare, and Incyte Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-11-18 10:21AM  Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales Zacks
08:00AM  Incyte to Report Third Quarter Financial Results Business Wire
Oct-09-18 07:30AM  Incyte Announces Data for Pemigatinib, its Selective FGFR Inhibitor, to be Featured at the ESMO 2018 Congress Business Wire
Oct-08-18 05:14PM  3 Top Biotech Stocks to Buy in October Motley Fool
11:15AM  Are These Beaten-Down Clinical-Stage Biotech Stocks Buys? Motley Fool
Oct-04-18 04:04PM  Tesla, Facebook, Amazon and Netflix Lead the Nasdaq's Sharp Decline -5.36%
Sep-28-18 06:16AM  Better Buy: Geron Corporation vs. Incyte Corporation Motley Fool
Sep-26-18 03:59PM  Stock News Today: Biotechs Help Nasdaq 100 To Day Of Outperformance Investor's Business Daily
Sep-20-18 02:18PM  Is Incyte Corporation (NASDAQ:INCY) As Strong As Its Balance Sheet Indicates? Simply Wall St.
Sep-18-18 06:18PM  Agenus Receives Milestone Payment of $5 Million from Incyte Zacks
Sep-13-18 09:00AM  In Honor of MPN Awareness Day and Blood Cancer Awareness Month, Incyte Debuts Documentary Spotlighting Myeloproliferative Neoplasms (MPNs) Business Wire
07:30AM  Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis Business Wire
Sep-12-18 10:41AM  Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars Zacks
09:11AM  Incyte, Foundation Medicine Partner for Companion Diagnostics Zacks
Sep-11-18 08:25AM  The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet Benzinga
07:30AM  Incyte and Foundation Medicine Announce Agreement to Develop Companion Diagnostic for Pemigatinib (INCB54828), a Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma Business Wire
Sep-09-18 04:46PM  The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs Benzinga
Sep-07-18 01:11PM  5 Stocks To Have On Your Radar Next Week Benzinga
Sep-06-18 04:30PM  Incyte Announces Chief Financial Officer David Gryska to Retire at the End of 2018 Business Wire
11:34AM  Why Incyte Stock Gained 11% in August Motley Fool
Aug-30-18 09:49AM  Why Is Incyte (INCY) Up 12.9% Since Last Earnings Report? Zacks
Aug-29-18 02:00PM  3 Stocks That May Lead a Massive Biotech Breakout Investopedia
Aug-23-18 10:00AM  Is Agenus Inc. Stock a Buy? Motley Fool
Aug-22-18 05:32PM  Gilead paid $510M for drug and just sold it for $3 million American City Business Journals
Aug-21-18 03:40PM  Incyte Has Quietly Risen 13 Percent In The Last Two Weeks, And That Uptrend Looks Like It Will Continue Benzinga
Aug-10-18 07:45AM  New Research: Key Drivers of Growth for United Rentals, DISH Network, Terex, Plains Group Holdings, The Hain Celestial Group, and Incyte Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-08-18 06:00AM  10 Undervalued Stocks With 'Exponential' Growth Potential Morningstar
Aug-06-18 04:00PM  This stock sector most often beats analysts estimates MarketWatch
06:54AM  3 Big Stock Charts for Monday: Entergy, Incyte and SL Green Realty InvestorPlace
Aug-01-18 01:24PM  Edited Transcript of INCY earnings conference call or presentation 31-Jul-18 12:00pm GMT Thomson Reuters StreetEvents
07:00AM  Incyte's Outlook Boosted by Robust Pipeline Morningstar
Jul-31-18 04:00PM  Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2 Zacks
08:30AM  Incyte (INCY) Lags Q2 Earnings Estimates Zacks
07:26AM  Incyte: 2Q Earnings Snapshot Associated Press
07:00AM  Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs Business Wire
06:00AM  Incyte Corporation to Host Earnings Call ACCESSWIRE
Jul-30-18 12:09PM  Could Gilead Merge With Pfizer Or Vertex To Solve Its CEO Problem? Investor's Business Daily
09:49AM  Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT Zacks
Jul-27-18 08:01AM  Incyte (INCY) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-26-18 06:32AM  Better Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation Motley Fool
Jul-24-18 01:25PM  NYSE trader: Amazon, Visa and Twitter earnings are on my radartheir charts are very similar Yahoo Finance Video
Jul-20-18 03:00PM  10 Cancer-Fighting Health Care Stocks to Buy Kiplinger
Jul-19-18 06:30PM  Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE) PR Newswire
11:14AM  CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA Zacks
09:38AM  Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2? Zacks
08:46AM  The 3 Worst Healthcare Stocks of 2018 (So Far) Motley Fool
Jul-15-18 03:42PM  Benzinga's Bulls & Bears Of The Week: AT&T, Facebook, Intel, Netflix, Twitter And More Benzinga
Jul-13-18 10:16AM  Incyte Has Limited Catalysts In Next 6 Months; But 2019 Could Be Pivotal, Morgan Stanley Says In Downgrade Benzinga
Jul-12-18 08:00AM  Incyte to Report Second Quarter Financial Results Business Wire
Jul-11-18 07:35AM  Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks ACCESSWIRE
Jul-01-18 05:28PM  Benzinga's Bulls & Bears Of The Week: Amazon, GE, Intel, T-Mobile And More Benzinga
Jun-27-18 08:12AM  Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod Zacks
08:00AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Incyte ACCESSWIRE
Jun-26-18 05:01PM  After the Bell: Back From the Abyss -6.97%
12:18PM  Incyte Downgraded As RBC Analyst Awaits More Revenue Visibility Benzinga
Jun-25-18 07:20AM  Blog Exposure Incyte's REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate of Ruxolitinib in Steroid-Refractory Acute GVHD ACCESSWIRE
Jun-22-18 09:12AM  Incyte (INCY) Announces Positive Results on Jakafi for GVHD Zacks
Jun-21-18 08:30AM  Incyte to Present Diversified Development Portfolio and Opportunities for Accelerated Growth at 2018 Investor and Analyst Event Business Wire
07:00AM  Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi®) in Steroid-Refractory Acute Graft-Versus-Host Disease Business Wire
Jun-11-18 02:58PM  Former Incyte CEO Buys Slumping Nektar Shares
06:45AM  Lilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology PR Newswire
Jun-10-18 09:40AM  3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate Motley Fool
Jun-08-18 09:37AM  Here's Why Incyte Rose 10.2% in May Motley Fool
Jun-05-18 06:02PM  Lifshitz & Miller LLP Announces Investigation of ARMO BioSciences, Inc., Financial Engines, Inc., Globalstar, Inc., Gridsum Holding Inc., InnerWorkings, Inc., Incyte Corporation, PPG Industries, Inc., and Spectrum Brands Holdings, Inc. PR Newswire
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naive acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESDirectorNov 08Buy68.771,00068,7656,668Nov 09 04:21 PM
SWAIN PAULA JEVP, Human ResourcesOct 03Option Exercise18.3210,000183,20042,324Oct 05 04:29 PM
Trower PaulPrincipal Accounting OfficerOct 03Option Exercise17.7910,000177,90024,172Oct 05 04:30 PM
Trower PaulPrincipal Accounting OfficerOct 03Sale70.0010,000700,00014,172Oct 05 04:30 PM
SWAIN PAULA JEVP, Human ResourcesOct 03Sale70.0010,000700,00032,324Oct 05 04:29 PM
Flannelly Barry PEVP & General Manager USOct 03Sale70.001,00070,00012,427Oct 05 04:23 PM
SWAIN PAULA JEVP, Human ResourcesSep 04Option Exercise18.3210,000183,20042,324Sep 06 04:30 PM
SWAIN PAULA JEVP, Human ResourcesSep 04Sale73.2110,000732,10032,324Sep 06 04:30 PM
SWAIN PAULA JEVP, Human ResourcesAug 21Option Exercise18.3210,000183,20042,324Aug 22 04:02 PM
SWAIN PAULA JEVP, Human ResourcesAug 21Sale70.0010,000700,00032,324Aug 22 04:02 PM
SWAIN PAULA JEVP, Human ResourcesJul 09Option Exercise18.3210,000183,20042,963Jul 11 04:41 PM
SWAIN PAULA JEVP, Human ResourcesJul 09Sale71.1110,000711,10032,963Jul 11 04:41 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJul 09Sale71.3460643,2328,103Jul 11 04:39 PM
BROOKE PAUL ADirectorJun 04Option Exercise2.8020,00056,000217,859Jun 06 04:33 PM
BAKER BROS. ADVISORS LPDirectorMay 02Option Exercise9.9260,000595,20029,267,937May 03 04:19 PM
Hoppenot HerveChairman / CEOMay 02Buy60.9415,000914,100276,690May 03 05:05 PM
SWAIN PAULA JEVP, Human ResourcesApr 30Option Exercise17.7980,0001,423,200107,267May 02 05:04 PM
SWAIN PAULA JEVP, Human ResourcesApr 30Sale62.4380,0004,994,40033,367May 02 05:04 PM
BROOKE PAUL ADirectorApr 05Option Exercise9.9220,000198,400217,859Apr 09 05:01 PM
GRYSKA DAVID WExecutive Vice President, CFOFeb 21Sale85.561,952167,01310,970Feb 22 04:46 PM
Huber Reid MEVP, Chief Scientific OfficerFeb 21Sale85.551,958167,50735,183Feb 22 04:23 PM
GRYSKA DAVID WExecutive Vice President, CFOJan 05Option Exercise83.836,760566,69120,752Jan 09 04:09 PM
GRYSKA DAVID WExecutive Vice President, CFOJan 05Sale98.876,760668,36113,992Jan 09 04:09 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 02Option Exercise72.865,000364,30013,676Jan 03 04:32 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 02Sale97.265,000486,3008,676Jan 03 04:32 PM